Korro Bio, Inc. (KRRO)
NASDAQ: KRRO · Real-Time Price · USD
13.50
-1.06 (-7.28%)
Jul 13, 2026, 4:00 PM EDT - Market closed
Korro Bio Revenue
Korro Bio had revenue of $3.84M in the twelve months ending March 31, 2026, down -20.31% year-over-year. In the year 2025, Korro Bio had annual revenue of $6.39M with 181.46% growth.
Revenue (ttm)
$3.84M
Revenue Growth
-20.31%
P/S Ratio
50.68
Revenue / Employee
$78,408
Employees
49
Market Cap
194.70M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 6.39M | 4.12M | 181.46% |
| Dec 31, 2024 | 2.27M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Codexis | 78.09M |
| Cellectis | 75.11M |
| Atrium Therapeutics | 36.68M |
| Voyager Therapeutics | 36.49M |
| Tonix Pharmaceuticals Holding | 17.56M |
| Whitehawk Therapeutics | 7.15M |
KRRO News
- 3 days ago - Korro Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 6 weeks ago - Korro Bio initiated with an Outperform at LifeSci Capital - TheFly
- 6 weeks ago - Korro to Present at the 2026 Jefferies Global Healthcare Conference - GlobeNewsWire
- 2 months ago - Korro Bio selects KRRO-111 as development candidate - TheFly
- 2 months ago - Korro Selects KRRO-111 as Development Candidate for the Potential Treatment of Alpha-1 Antitrypsin Deficiency (AATD) - GlobeNewsWire
- 2 months ago - Korro Bio price target lowered to $15 from $20 at H.C. Wainwright - TheFly
- 2 months ago - Korro Bio initiated with a Buy at Citi - TheFly
- 2 months ago - Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire